# A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.

> **NCT00317174** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 450 (—)

## Conditions studied

- Haemophilus Influenzae Type b
- Tetanus
- Whole Cell Pertussis
- Hepatitis B
- Diphtheria

## Interventions

- **BIOLOGICAL:** DTPw-HBV/Hib-MenAC conjugate vaccine

## Key facts

- **NCT ID:** NCT00317174
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2004-04
- **Target enrollment:** 450 (—)
- **Last updated:** 2016-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317174, "A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00317174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*